Doximity (NYSE:DOCS) Upgraded to Hold at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Doximity (NYSE:DOCSFree Report) from a strong sell rating to a hold rating in a research report sent to investors on Friday,Zacks.com reports.

Several other equities analysts also recently issued reports on the stock. Barclays upgraded shares of Doximity to a “strong-buy” rating in a report on Monday, December 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Doximity in a research note on Wednesday, December 24th. Finally, Wall Street Zen cut shares of Doximity from a “buy” rating to a “hold” rating in a report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy”.

View Our Latest Report on DOCS

Doximity Trading Up 0.3%

Shares of NYSE:DOCS opened at $43.85 on Friday. Doximity has a 1 year low of $43.21 and a 1 year high of $85.21. The stock has a market cap of $8.26 billion, a P/E ratio of 34.80, a price-to-earnings-growth ratio of 2.03 and a beta of 1.39.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

  • Positive Sentiment: Truist upgraded DOCS from “hold” to “strong-buy,” signaling conviction in near-term upside and product/market momentum that could support a rebound in shares. Truist Upgrade
  • Positive Sentiment: Royal Bank of Canada (RBC) moved DOCS to a “moderate buy,” citing a durable growth moat—this bolsters the long-term growth thesis and may attract buyers looking past recent volatility. RBC Coverage
  • Positive Sentiment: Goldman Sachs upgraded DOCS from “strong sell” to “hold” — a move that reduces downside risk from a major house, even as Goldman warns of a valuation reset; the change can remove selling pressure tied to the prior very negative rating. Goldman Upgrade
  • Neutral Sentiment: Coverage pieces assess DOCS vs. peers and provide a critical review of positioning—useful context for investors but not an immediate catalyst by themselves. Competitor Review
  • Neutral Sentiment: Yahoo Finance examines valuation after volatile trading and discusses recent AI product updates; product developments are positive, but valuation and volatility keep the near-term outlook mixed. Valuation & AI Update
  • Negative Sentiment: Wall Street Zen lowered DOCS to a “hold,” which could add selling pressure among investors who react to fresh downgrades and heighten short-term caution. Wall Street Zen Downgrade

Doximity Company Profile

(Get Free Report)

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.

Featured Articles

Analyst Recommendations for Doximity (NYSE:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.